APA (7th ed.) Citation

CS, G., A, P., E, B., M, W., S, S., TI, d. S., . . . P, K. (2024). Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): An open-label, multicentre, randomised, controlled, phase 3 trial. The Lancet. Rheumatology, 6(6), e339. https://doi.org/10.1016/S2665-9913(24)00065-1

Chicago Style (17th ed.) Citation

CS, Goodyear, et al. "Immunogenicity of Third Dose COVID-19 Vaccine Strategies in Patients Who Are Immunocompromised with Suboptimal Immunity Following Two Doses (OCTAVE-DUO): An Open-label, Multicentre, Randomised, Controlled, Phase 3 Trial." The Lancet. Rheumatology 6, no. 6 (2024): e339. https://doi.org/10.1016/S2665-9913(24)00065-1.

MLA (9th ed.) Citation

CS, Goodyear, et al. "Immunogenicity of Third Dose COVID-19 Vaccine Strategies in Patients Who Are Immunocompromised with Suboptimal Immunity Following Two Doses (OCTAVE-DUO): An Open-label, Multicentre, Randomised, Controlled, Phase 3 Trial." The Lancet. Rheumatology, vol. 6, no. 6, 2024, p. e339, https://doi.org/10.1016/S2665-9913(24)00065-1.